Merck-Controlled Joint Venture With Simcere Opens Before Schedule
This article was originally published in PharmAsia News
Executive Summary
Simcere MSD (Shanghai) Pharmaceutical Co. Ltd., 51% owned by Merck & Co. Inc. and 49% by Simcere Pharmaceutical Group, began operations Sep. 12, originally scheduled for 2013.
Simcere MSD (Shanghai) Pharmaceutical Co. Ltd., 51% owned by Merck & Co. Inc. and 49% by Simcere Pharmaceutical Group, began operations Sep. 12, originally scheduled for 2013. Simcere President Zhang Yehong is the CEO of the new joint venture and Lei Nuode is the chief operating officer. The JV will combine its parent companies’ expertise in R&D, production and sales, focusing on chronic illness treatments in the primary care market. The cooperation is prompted by the two companies’ operational similarities, Merck’s advanced innovation capabilities and plans for long-term business in China, and Simcere’s domestic sales network reaching over 4,000 hospitals and 70,000 drugstores. (Click Here For More - Chinese Language
)
"Simcere-MSD JV Opens Today, 51% Owned By Merck" - health.xinmin.cn (9/12/2012)